Zurzuvae Capsule
Product Images NDC 64406-029

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zurzuvae (NDC 64406-029). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biogen Ma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zur00 0003 01)

Chemical structure of zuranolone, showing its steroid-like framework with multiple rings, hydroxyl groups, and a nitrile substituent, consistent with the active ingredient in ZURZUVAE capsules.*

FDA Label Image

Figure 1 (Zur00 0003 02)

A forest plot chart depicting the change ratio to reference with 95% confidence intervals for various subgroups including age groups, sex, race, ethnicity, medication use, and scores. The x-axis represents the change ratio scale, and each subgroup's data point with confidence intervals is visualized to compare effect sizes relative to a reference.*

FDA Label Image

Figure 2 (Zur00 0003 03)

A data table comparing pharmacokinetic parameters including Cmax and AUC for zuranolone with different test conditions and solvents such as cyclodextrin and ethanol. The table displays numerical values and changes relative to a reference, indicating variations in compound interactions across formulations.*

FDA Label Image

Figure 3 (Zur00 0003 04)

A line graph comparing serum zuranolone concentration (ng/mL) over time (hours) between placebo and ZURZUVAE 30 mg oral capsule. The X-axis shows time points up to 48 hours, and the Y-axis shows concentration levels. The graph indicates higher serum concentrations for ZURZUVAE compared to placebo, with noted dosing periods.*

FDA Label Image

Principal Display Panel (30 mg Bottle Carton)

Label of ZURZUVAE (zuranolone) 30 mg oral capsules showing the product name, strength, and dosage form. The label identifies this as a prescription drug, indicates oral use, and specifies it contains 14 capsules. It includes a note to dispense with the accompanying Medication Guide and displays the NDC 64406-031-01 and the labeler Biogen MA Inc.*

FDA Label Image

Principal Display Panel (25 mg Blister Pack Carton)

ZURZUVAE (zuranolone) capsules 25 mg per capsule oral dosage form. The label indicates a 14-day blister pack containing 28 capsules, with a recommended daily dose of 50 mg. Labeler is Biogen MA Inc. Additional instructions include dispensation with accompanying Medication Guide.*

FDA Label Image

Principal Display Panel (20 mg Bottle Carton)

ZURZUVAE 20 mg capsules containing zuranolone are shown in this partial packaging label. The product is for oral use, dispensed with an accompanying Medication Guide, with a package size of 14 capsules. The label indicates prescription use only and displays a Roman numeral IV.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.